23andMe Holding Co.

Type: Public company (NYSE: ME) Founded: 2006 Co-founders: Anne Wojcicki, Linda Avey, Paul Cusenza Headquarters: Sunnyvale, California Business: Direct-to-consumer genetic testing and research platform Revenue Model: DNA test kits ($99-199), subscription services, data licensing for pharmaceutical research Database: 14+ million customers genotyped (one of world's largest genetic databases) Notable Early Funding: Google invested $3.9M in 2007 (Sergey Brin connection) Total raised: ~$786M+ across multiple rounds SPAC merger with VG Acquisition Corp in 2021 Status: Struggling financially (2023-2024) Stock trading near $0.10/share (down from $17+ peak in 2021) Market cap under $200M (Dec 2024) Workforce reductions: 40% layoff in Oct 2024 (~200 employees) Exploring strategic alternatives including potential sale NYSE delisting concerns due to sustained low stock price Board crisis: All independent directors resigned Sept 2024 Therapeutics division shut down in Nov 2024 Financial sustainability in serious question